Dice Therapeutics — DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild-to-moderate psoriasis · Slide 12022
Dice Therapeutics — DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild-to-moderate psoriasis · Slide 22022
Dice Therapeutics — DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild-to-moderate psoriasis · Slide 32022
Dice Therapeutics — DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild-to-moderate psoriasis · Slide 42022
Dice Therapeutics — DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild-to-moderate psoriasis · Slide 52022
Dice Therapeutics — DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild-to-moderate psoriasis · Slide 62022
Dice Therapeutics — DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild-to-moderate psoriasis · Slide 72022
Dice Therapeutics — DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild-to-moderate psoriasis · Slide 82022
Dice Therapeutics — DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild-to-moderate psoriasis · Slide 92022
Dice Therapeutics — DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild-to-moderate psoriasis · Slide 102022
Dice Therapeutics — DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild-to-moderate psoriasis · Slide 112022
Dice Therapeutics — DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild-to-moderate psoriasis · Slide 122022
Dice Therapeutics — DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild-to-moderate psoriasis · Slide 132022
Dice Therapeutics — DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild-to-moderate psoriasis · Slide 142022